Posted by Michael Wonder on 14 Sep 2022
aTyr Pharma receives FDA fast track designation for efzofitimod for treatment of systemic sclerosis-associated interstitial lung disease
13 September 2022 - Second fast track designation for efzofitimod clinical program.
aTyr Pharma today announced that the US FDA has granted the company fast track designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc, also known as scleroderma)-associated, interstitial lung disease.
